KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $96.8 million.

  • Neogenomics' Operating Expenses rose 114.89% to $96.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $430.2 million, marking a year-over-year increase of 1255.03%. This contributed to the annual value of $430.2 million for FY2025, which is 1255.03% up from last year.
  • Per Neogenomics' latest filing, its Operating Expenses stood at $96.8 million for Q4 2025, which was up 114.89% from $107.5 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Operating Expenses ranged from a high of $124.9 million in Q2 2025 and a low of $56.7 million during Q1 2021
  • Over the past 5 years, Neogenomics' median Operating Expenses value was $89.8 million (recorded in 2023), while the average stood at $90.8 million.
  • In the last 5 years, Neogenomics' Operating Expenses skyrocketed by 7603.04% in 2021 and then plummeted by 416.47% in 2022.
  • Over the past 5 years, Neogenomics' Operating Expenses (Quarter) stood at $86.8 million in 2021, then dropped by 4.16% to $83.2 million in 2022, then rose by 3.55% to $86.2 million in 2023, then grew by 11.02% to $95.7 million in 2024, then grew by 1.15% to $96.8 million in 2025.
  • Its last three reported values are $96.8 million in Q4 2025, $107.5 million for Q3 2025, and $124.9 million during Q2 2025.